Human granulocytic anaplasmosis (HGA), an emerging tick-borne disease, poses significant public health challenges due to its increasing incidence and potential severity. As a research service provider with strong comprehensive strength, our company is committed to providing professional and comprehensive HGA vaccine and therapy development solutions to global pharmaceutical companies.
Introduction to Human Granulocytic Anaplasmosis
HGA is a rickettsial infection transmitted primarily by the Ixodes scapularis tick, commonly found in the Northeast and Upper Midwest regions of the United States. The causative agent, Anaplasma phagocytophilum, manipulates host neutrophils, altering their gene expression to prolong their lifespan and facilitate bacterial replication. While many patients recover spontaneously, a concerning percentage can develop life-threatening complications, underscoring the urgency for effective therapeutics and preventive measures.
Fig.1 List of countries where the case reports originated. (Dumic I., et al., 2022)
Vaccine Development for Human Granulocytic Anaplasmosis
The quest for an HGA vaccine has intensified due to the disease's rising prevalence and the absence of a specific cure. Vaccine development focuses on eliciting an immune response against A. phagocytophilum to prevent infection or ameliorate disease severity. The main strategies include:
Recombinant Proteins
Developing proteins that can stimulate a protective immune response without causing disease.
Subunit Vaccines
Utilizing purified components of the bacterium to induce immunity.
Vectored Vaccines
Employing modified viruses to deliver A. phagocytophilum antigens.
Therapeutics Development for Human Granulocytic Anaplasmosis
The nonspecific early symptoms of HGA often lead to delayed diagnosis, impacting the effectiveness of antibiotic therapy. In addition, the potential for co-infection with other tick-borne pathogens like Borrelia burgdorferi and Babesia microti complicates therapeutic strategies.
- Doxycycline: As the first-line therapeutic, doxycycline has demonstrated efficacy in vitro and in clinical practice, with most patients showing significant improvement within 24-48 hours of therapeutic initiation.
- Rifamycins: Effective in vitro, rifampin serves as an alternative for patients unable to tolerate tetracyclines, including pregnant women and children under 8.
- Fluoroquinolones: While showing some in vitro activity, clinical evidence suggests potential limitations in efficacy for HGA therapeutics.
To explore further details about our comprehensive range of therapy development solutions, we invite you to click on the link provided below.
Our Services
At our esteemed organization, we provide an extensive array of HGA research services aimed at facilitating the advancement of vaccine and therapy development. Equipped with cutting-edge facilities and a team of seasoned scientists, we offer the following key capabilities:
Disease Models
- C3H/HeN Mouse Infection Models
- SCID Mouse Infection Models
- BALB/c Mouse Infection Models
- Canine Infection Models
- Customized Animal Models
Preclinical Research
- Drug Safety Evaluation
- In Vivo Pharmacokinetics Study
- In Vitro Pharmacokinetics Study
- Activity Testing
- Drug Resistance Evaluation
We conduct extensive in vitro and in vivo studies to evaluate the safety, immunogenicity, and efficacy of HGA vaccine and therapeutic candidates. Our preclinical research services include cell-based assays, animal models, and comprehensive toxicology assessments. If our services have piqued your interest, we warmly welcome you to reach out to us for further information and to obtain a detailed quotation for the services you require.
Reference
- Dumic Igor, et al. "Human granulocytic anaplasmosis—a systematic review of published cases." Microorganisms 10.7 (2022): 1433.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
